1. Home
  2. GRND vs WGS Comparison

GRND vs WGS Comparison

Compare GRND & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grindr Inc.

GRND

Grindr Inc.

HOLD

Current Price

$13.48

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$66.34

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRND
WGS
Founded
2009
2017
Country
United States
United States
Employees
148
1300
Industry
Computer Software: Prepackaged Software
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GRND
WGS
Price
$13.48
$66.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$18.80
$120.71
AVG Volume (30 Days)
1.0M
580.4K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.08
$29.98
Revenue Next Year
$17.04
$25.92
P/E Ratio
N/A
$1,251.58
Revenue Growth
N/A
N/A
52 Week Low
$9.79
$55.17
52 Week High
$25.13
$170.87

Technical Indicators

Market Signals
Indicator
GRND
WGS
Relative Strength Index (RSI) 63.94 46.64
Support Level $12.91 $56.24
Resistance Level $14.12 $73.46
Average True Range (ATR) 0.45 4.29
MACD 0.06 0.93
Stochastic Oscillator 78.82 56.96

Price Performance

Historical Comparison
GRND
WGS

About GRND Grindr Inc.

Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: